To ATCC Valued Customers,

ATCC stands ready to support our customers’ needs during the coronavirus pandemic. If you experience any issues with your products or services, please contact ATCC Customer Service at sales@atcc.org. For Technical questions please contact tech@atcc.org. Thank you.
X

Privacy Policy Update

We remain dedicated to protecting your data and experience throughout our platforms. We have updated our Privacy Policy and your continued use of the Site means you have accepted the revised Privacy Policy. View now >
X

FAQ's

FAQ Home

Find Answers

Validation - CRL-2003IG

How is the IDH2R140Q human isogenic leukemia cell line (ATCC® CRL-2003IG ™) validated?

This line has been tested in parallel with its parental line at the genomic, transcript and cellular levels as well as assayed for the desired phenotypic functional activity resembling the intended genotypic IDH2R140Q knock-in mutation.  Elevated 2-hydroxyglutarate or (2-HG) levels in the IDH2R140Q mutant isogenic line are observed, above the WT parental cell line, and hypermethylation detected by western blotting for H3K4me3 and H3K27me3 histone markers. 

The IDH2R140Q acute myeloid leukemia isogenic line was tested with two IDH2 specific inhibitors:  AGI-6780 and AG-221.  A reduction in histone methylation compared to the untreated and DMSO groups was observed.  In addition, the 2-hydroxyglutarate (2-HG) levels in our WT parental samples were unaffected by the drug treatment whereas the IDH2R140Q isogenic mutant showed remarkably high levels of 2-HG secreted in untreated and DMSO control treated groups and a reduction in the 2-HG levels when treated with AGI-6780 and AG-221.  

Date Created10/03/2017 12:04 PM
Date Updated10/03/2017 12:05 PM

Most Popular Answers

  1. Huh7 cell line
  2. ATCC HUVEC lines
  3. Passage number vs. population doubling level (PDL)
  4. Converting TCID[50] to plaque forming units (PFU)
  5. U-373 MG (ATCC® HTB-17)